Design of Drug Molecule Based Structure for Smad 3 Protein and Its Insilico Investigations of Leukemia Utilizing Bioinformatics Software
A. Manikandan1, T. Jayalakshmi2, P.B. Ramesh Babu3
1A. Manikandan, Department of Genetic Engineering, / Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India
2T. Jayalakshmi, Department of Genetic Engineering, Student of Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India
3P.B. Ramesh Babu, Department of Genetic Engineering, Student of Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu,India
Manuscript received on 18 June 2019 | Revised Manuscript received on 25 June 2019 | Manuscript published on 30 June 2019 | PP: 1199-1202 | Volume-8 Issue-5, June 2019 | Retrieval Number: E7091068519©BEIESP/19©BEIESP
Open Access | Ethics and Policies | Cite | Mendeley | Indexing and Abstracting
© The Authors. Blue Eyes Intelligence Engineering and Sciences Publication (BEIESP). This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Abstract: The Research work on rational drug molecules design for Smad3,the conclusion is that out of all the inhibitors chosen for the docking , PTHrP emerged to be the best inhibitor for the protein Smad3.The precise reason for it was its docking energy which was the lowest (docked energy =-29.73), among all other inhibitors used. Hence the conclusion is that Smad3 is the best inhibitor, for Smad3. Hence the task was completed successfully. There are many reasons and factors responsible for induction of cancer. Leukemia is a type of cancer in blood or bone marrow and is characterized by an irregular proliferation of white blood cells.
Keywords: Design of Drug Molecule Based, Proliferation, PTHrP,
Scope of the Article: Healthcare Informatics